Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 … Next › Last »

Prevision Policy Clips | PDUFA Reauthorization Kick Off Meeting Set For July 14

May 8, 2025

Opioid Post-Marketing Studies Praised For “Rigor,” But FDA Committee Wary Of Labeling Changes; Discussion Highlights Ongoing Concerns About Long-Term Efficacy

May 7, 2025

HHS Deputy Nominee O’Neill Cites Value Of AI, Support For Medicare Drug Price Negotiation And Vaccines During Confirmation Hearing; RFK “Doing A Great Job”

May 7, 2025

Prevision Policy Clips | FDA Schedules Last-Minute ODAC Review Of Four Oncology Drugs May 20-21

May 7, 2025

CBER Director Vinay Prasad Solidifies FDA’s Anti-Industry Identity, Brings Increased Scrutiny To Use Of Accelerated Approval In Cancer, Gene Therapies

May 6, 2025

White House Drug Manufacturing EO Seeks To Streamline Domestic Site Inspections, Accelerate Foreign Audits – But RIFs, Long-Standing Challenges Will Be Reality Check

May 6, 2025

Prevision Policy Clips | FDA Directed To Streamline Domestic Inspections, Accelerate Foreign Ones

May 6, 2025

Prevision Policy Clips | FDA Not Mentioned In “Skinny Budget” Unveiled By Trump Administration May 2

May 5, 2025

BIOSECURE Likely to Be Reintroduced Soon In Modified Form; China-Focused Biotech Bills Could Proliferate In 2025

May 2, 2025

Prevision Policy Clips | NIH “Generation Gold Standard” Vaccine Initiative Targets 2029 FDA Submissions For Two Universal Flu

May 2, 2025

Price Negotiation Year Two: CMS Town Hall Shows Little Change In Tone Under Trump; Ozempic, Trelegy Ellipta, And Xifaxan Get Mixed Comments

May 1, 2025

FDA Opioid Advisory Committee Will Consider Labeling Changes To “Quantify” Risks Based On Post-Marketing Trials; First Panel Of Kennedy/Makary Era Will Still Include Industry Rep

May 1, 2025

House Energy & Commerce Committee Advances Six Bipartisan Health Bills; PBM And PRV Measures Remain TBD

May 1, 2025

FDA Deadline Tracker: Missed Deadlines Make News In April After Layoffs To Start The Month

May 1, 2025

Prevision Policy Clips | Alliance For A Stronger FDA Applauds Commissioner Makary’s Decision To Drop Reorg Plan

May 1, 2025

Prevision Policy Clips | HHS Deputy Nominee O’Neill Confirmation Hearing Set For May 6

April 30, 2025

FDA Reorg Plan Will Not Move Forward, Commissioner Makary Says; “Single Center” Idea Appears Dead For Now: Possible Turning Point For FDA Under Trump?

April 29, 2025

Advisory Committee Tracker: COVID Booster Panel Could Be Tone-Setter For Makary’s Tenure – If It Happens; FDA Public Meeting Cancellations Continue Into Spring

April 29, 2025

Prevision Policy Clips | No FDA Reorganization Planned, Commissioner Makary Says

April 29, 2025

Prevision Policy Clips | Novavax COVID Vaccine Delay: Commissioner Makary Confirms Demand For Clinical Trial

April 28, 2025

Prevision Policy Clips | Merck, Bristol Reassure Investors That FDA Reviews Are Proceeding On Time For Now

April 25, 2025

340B Contract Pharmacy Restrictions’ Impact Is Waning, Manufacturers Tell Sen. Cassidy; Report Quantifies Effect On Lilly, J&J, And Amgen, Fuels Cassidy’s Call For Reforms

April 24, 2025

FDA Expands Catalogue Of Rare Disease Case Studies: New Examples Look At Surrogate Endpoints (Qalsody, Nexviazyme, Livdelzi), Externally Controlled Trials (Amvuttra) And Novel COAs (Bylvay)

April 24, 2025

Making “Cost-Effective” Drugs “Affordable”: ICER Obesity White Paper Offers Options To Expand Access To GLP-1s For Insurers, Policymakers To Consider

April 24, 2025

Prevision Policy Clips | FDA Rare Disease Case Studies Include Biogen’s Qalsody And Alnylam’s Amvuttra

April 24, 2025
1 2 3 4 5 … Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Copyright © 2025 Prevision Policy. All Rights Reserved. Privacy Policy